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ABSTRACT 
 
Transgenic technologies can provide important animal models for studying drug-metabolizing enzymes. Our 
overall aim was to generate versatile cell and animal systems that exhibited varying levels of cytochrome 
P450 oxidoreductase (POR) activity, more accurately modelling the human population for pharmacological 
and toxicology studies. Towards this goal we evaluated RNA-interference constructs designed for use in 
vitro and in vivo for reducing POR activity in hepatocytes. This study clearly demonstrates that both POR 
protein level and reductase activity can be significantly knocked down in Hepa-1 cells in vitro, while 
highlighting the difficulty in predicting knockdown efficiency in transgenic animals. The high levels of 
embryonic lethality observed, and inability to produce multi-copy transgenic animals indicates that high 
levels of shRNA expression may be detrimental to embryonic development. 
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INTRODUCTION 
 
The metabolism of drugs leading to functional 
modification or degradation occurs primarily in the liver. 
This process represents an important determinant of the 
duration and intensity of the pharmacological action of 
drugs (Thummel et al, 1997), with outcomes ranging from 
complete detoxification to the production of metabolites 
that are more toxic than the original drug. Phase I 
reactions can either activate or inactivate a drug through a 
variety of biochemical reactions, with the majority of 
oxidative events occurring through the cytochrome P450 
(CYP) family of enzymes (Nebert et al, 1996). Phase II 
reactions often function on Phase I generated metabolites, 
and involve drug-conjugating enzymes that usually result 
in detoxification (Sheenan et al, 2001). 
The liver represents a major site of Phase I drug 
metabolism through the function of the CYP enzymes 
(Nebert et al, 1996). The significant variability in drug 
clearance and clinical response observed between 
individuals often reflects differences in CYP activity 
(Ingelman-Sundberg, 2004). The CYP monoxygenases 
represent a large family of genes that are broadly classified 
into two groups (Nelson, 1999); those involved in drug 
metabolism and xenobiotic clearance, which are present at 
variable levels in different individuals, and those required 
for specific biological pathways including cholesterol 
biosynthesis, retinoic acid metabolism and steroid 
biosynthesis. All CYP enzymes are activated by 
NADPH:Cytochrome P450 Oxidoreductase (POR; 
E.C.1.6.2.4). POR catalyses the transfer of electrons from 
NADPH to CYP enzymes and in the absence of POR, 
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CYP enzymes are essentially inactive. The interaction of 
drugs with CYP enzymes, and subsequent alteration of 
CYP activity, is a major source of adverse drug reactions. 
 
Transgenic technologies can provide important animal 
models for studying drug-metabolizing enzymes, 
specifically, animals can be engineered to enable studies on 
the regulation of enzymatic expression and the impact of 
variable levels of enzyme activity on pharmacological 
action and associated toxicity. The multiple genes that 
encode CYP enzymes, and their overlapping functions, 
make the analysis of gene knockout studies difficult 
(Henderson et al, 2003). An alternative approach has been 
to knockout POR, thereby affecting all CYP activity. The 
POR-null mutation in mice is embryonic lethal (Shen et al, 
2002; Wu et al, 2005), but conditional knockout strategies 
have shown the value of this approach to understanding 
drug metabolism (Henderson et al, 2003; Finn et al, 2007). 
Mice lacking hepatic POR are viable and fertile, but 
completely devoid of liver CYP activity, and are unable to 
metabolize testosterone, acetaminophen and pentobarbital 
(Henderson et al 2003). With the aim to develop transgenic 
strategies providing intermediate POR activities, in this 
study we have evaluated RNA-interference (RNAi) 
approaches to knockdown POR activity in the mouse liver. 
 
MATERIALS AND METHODS 
 
Vector construction 
shRNA vectors were obtained from Sigma expressing 
various short hairpin sequences under the control of the 
human ubiquitous U6 pol-III promoter. 
 
Target sequences:  
 
shPOR1: 5'CCTGACCTACTGGTTCATCTT 
shPOR2: 5'CGGAGGCACATCCTAGCCATT 
shPOR3: 5'GCATCTAATGCACCTGGAATT 
shPOR4: 5'CGGGAAGGAACATTATTGTAT 
shPOR5: 5'GCTCGAAATATGGCCAAAGAT 
 
These vectors contained a puromycin resistance gene 
under the control of a PGK promoter. This was removed 
using Nsi I and Bam HI, the backbone was blunted and a 
blunt ended eGFP fragment was ligated into the plasmid 
using T4 DNA ligase.  
 
Lentivirus production 
Self-inactivating (SIN) lentivirus was generated by 
Fugene-6 (Roche) mediated co-transfection of the three 
plasmids encoding the required packaging proteins, 
envelope and viral genome – 12μg psPAX2, 6μg VSV-G 
and 9μg pLKO-shRNA, repectively – a T150 flask seeded 
the previous day at 1x107 cells per flask (Al Yacoub et al, 
2007). Conditioned medium was removed at 24hr and 
48hr, filtered and centrifuged at 7,000xg O/N at 4°C, the 
resultant pellet was resuspended in 5ml TSSM buffer 
consisting of 20mM Tris, pH 7.3, 100mM sodium 
chloride, 10mg/ml sucrose and 10mg/ml mannitol, and 
concentrated by ultra-centrifuge at 20,000xg for 2hr at 
4°C. The viral pellet was then resuspended in 100µl TSSM 
and aliquoted for storage at -80°C. Virus titres were 
determined by Polybrene-mediated serial dilution 
transduction of HT1080 cells and GFP expressing positive 
colonies were counted after 5 days (Al Yacoub et al, 
2007). Concentrated viral titres ranged from 3.8x109 
TU/ml to 6x109 TU/ml.  
 
Cell culture and lentivirus transduction 
Hepa-1 cells were grown at 37°C (5%, v/v, CO2) in 
Dubelecos modified Eagle medium (DMEM) 
supplemented with 10% (v/v) foetal calf serum (FCS, 
Gibco). Cells were grown to 80-90% confluence before 
being passaged. Hepa-1 cells were seeded at ~12000 cells 
per well in a 24-well plate 24hr prior to transduction with 
lentivirus at a multiplicity of infection (MOI) of ~1 in the 
presence of 8µg/ml polybrene. The cells were then FACS 
sorted to isolate the cells into which the pro-virus had 
integrated and maintained as a pooled population for no 
more than 10 passages. 
 
POR expression and functional assays 
Microsomal protein extracts were purified from Hepa-1 
cells and mouse tissue using Sigma Endoplasmic 
Reticulum Extraction kit following the manufacturer’s 
protocol. Protein concentration was determined using 
BCA protein assay kit (Thermo Scientific) and expression 
was analysed by western blot employing ECL detection. 
POR detection was through rabbit CH59 anti-POR 
polyclonal antibody (kind gift from Colin Henderson, 
Dundee University: Henderson et al, 2003) and 
horseradish peroxidise labelled polyclonal goat anti-rabbit 
antibody (Dako). POR levels were normalised to β-actin 
using anti-mouse β-actin (Sigma) and goat anti-mouse 
(Dako) antibodies. The intensity of the bands was then 
quantified using PhosphorImager and QuantityOne 
software.  The reductase activity of microsomal POR was 
determined using a colorimetric Cytochrome P450 
reductase assay kit (Sigma) following the manufacturer’s 
protocol (Plonne et al, 1999).  
 
Generation of transgenic mice 
All animal experimentation was performed after review by 
Animal Ethics Committee and under UK Home Office 
Licence. Transgenic mice were generated as described 
previously (Ritchie et al, 2007).  Eggs harvested from 
super-ovulated C57BL6 X CBA females were injected 
with a 10x or 1x pulse of ~50pl of 109 TU/ml1080 virus 
using standard micro-injection procedure.  The virus was 
injected into the peri-vitellin space using a glass 
microinjection needle.  Following injection the eggs were 
transferred to M16 medium (Sigma) for incubation at 
37°C 5% (v/v) CO2 until day 4.5 where 15-18 developed 
blastocysts were surgically implanted into a psuedo-
pregnant female.  The resultant pups were genotyped by 
Southern blot (Whitelaw et al, 1992) and PCR (Vasey et 
al, 2008), using either: 
 
eGFP-F: 5’CACATGAAGCAGCACGACTT with 
eGFP-R: 5’TCTGGGTGGACAGGTAGTGG; or 
 
HIVpsiF: 5’GAGAGAGATGGGTGCGAGAAG with 
HIVpsiR: 5’GCTGTGCGGTGGTCTTACTT  
 
as previously described. Transgenic mice were bred with 
C57BL6 X CBA F1 stock mice. 
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RESULTS 
 
Evaluation of shRNA vectors in vitro 
POR knockdown was analysed by western blot in shPOR1 
(72%), shPOR4 (55%) and shPOR5 (49%) transduced cell 
populations although given the variance between replicates 
only the reduction observed in shPOR1 cells was 
statistically significant (Figure 1). To determine if the 
shRNA knockdown of POR protein levels influenced 
hepatic cellular function we performed a reductase assay 
(Plonne et al, 1999). The lowest reductase levels were 
consistently observed for shPOR1 and shPOR5, reflecting 
the POR expression levels both showing a significant 
reduction in P450 reductase activity (Figure 1). The 
relatively high variance observed between replicates  could 
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Figure 1.  POR expression and function in Hepa1 cells treated 
with shPOR lentivirus. Transduction of Hepa-1 cells with one of 
6 shRNAs (shPOR1, shPOR2, shPOR3, shPOR4, shPOR5, 
shPOR-ve) and POR protein determined by western blot (A) with 
average densitometry data (B) normalized to β-actin protein 
levels with error bars showing Standard Deviation (n=3). POR 
protein levels are shown relative to that detected in non-
tranfected cells (horizontal line). Cytochrome C reductase 
activity (C) of microsomal protein with error bars representing 
the Standard Deviation (n=3). Reductase activity shown relative 
to that detected in non-tranfected cells (horizontal line). 
 
be a consequence of varying numbers of viral integration 
events between the examined samples. A subsequent 
experiment, where cells were sorted according to GFP 
expression, indicated that those cells expressing higher 
levels of GFP grew slower than those expressing lower 
levels of GFP and when re-analysed by FACS their GFP 
expression profile had changed (data not shown). Higher 
GFP expression was assumed to be as a result of a greater 
number of integration events, and thus it may be that these 
cells also express higher quantities of shRNA. This 
suggests that there may be a significant reduction in 
growth rate or even toxicity associated with high numbers 
of integration events and transgene expression, indeed 
toxicity has previously been reported in cells expressing 
high levels of shRNAs (Fish et al, 2004). This shift in 
population may have affected different experimental 
replicates to a greater or larger degree resulting in a high 
variance in expression and activity read-outs.     
 
Evaluation of shRNA vectors in vivo 
shRNAs shown to give different levels of knockdown 
were used to generate transgenic animals. We attempted 
two separate peri-vitelline injection regimes in an attempt 
to get various levels of POR knockdown depending on 
transgene copy number; 1x50pl and 10x50pl of high-titre 
lentivirus (at least 3.8x109 TU/ml), the outcome of all the 
injections carried out are summarised in Table 1. Initial 
development of embryos to blastocysts showed a 
considerably lower level of development in the 10x 
injection batch (1x50pl: 241/376 (64%); 10x50pl: 143/375 
(38%)) in all viral injections. This indicates that high 
concentrations of viral particles and/or shRNA expression 
reduce blastocyst development irrespective of target 
sequence. Integrational mutagenesis is a recognised 
problem of using lentiviruses however studies using 
similar injection strategies showed no significant reduction 
in development where up to 21 transgene integration 
events were seen (Lois et al, 2002; Ritchie et al, 2007), 
indicating that this may be a symptom of high levels of 
shRNA expression. 
 
1x50pl injection of shPOR1 into developing zygotes 
yielded three founder transgenic mice that were identified 
as positive by PCR of tail clip biopsy DNA, Southern blot 
analysis showed each positive contained only one copy of 
the shPOR1 transgene (data not shown); offspring were 
bred from two of the founder animals and genotyped by 
Southern blot (Figure 2A) and PCR. Liver microsomal 
protein extracts from the off-spring were analysed by 
western blot and Cytochrome P450 reductase assay 
(Figure 3). A clear relationship between POR expression 
and reductase activity was observed in these mice (Figure 
3C) but, overall, no significant difference in POR 
expression or reductase activity was observed when 
compared to wild-type (WT) littermates. 
 
Curiously all transgenic mice successfully raised carried 
only one copy of the transgene (Figure 2); similar studies 
have shown both higher efficiency of transgenesis and the 
generation of multicopy transgenic animals using similar 
quantities of virus (Lois et al, 2002). It is conceivable that 
in our study, any multicopy animals, which would  
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Table 1. Summary of blastocyst transfers, pregnancies, birth rates and transgenesis. The efficiency of development to blastocyst 
stage, through gestation to birth varied between viruses and injection regime. Several preganncies did not come to term (* denotes 
pups reabsorbed, consumed at birth or died within 3 days of birth) and those that did showed low levels of transgenesis. 
 
Virus Injection regime 
Blastocyst 
transfers 
(x18) 
Pregnancies 
(<10days) Litters Pups GFP Transgenic 
shPOR1 10x 2 1 1 /* /* / 
shPOR1 1x 5 3 3 11 11 7 
shPOR4 10x 5 4 4 /* /* / 
shPOR4 1x 3 2 2 0 0 0 
shPOR-ive 10x 4 1 1 4* 4 4 
shPOR-ive 1x 4 3 3 18 0 1 
 
 
 
 
A:            B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Southern blot analysis of transgenic pups. The mating of shPOR1.1 and shPOR1.2 founder animals with WT females gave 
two litters of which 6 were transgenic and they all contained one copy of the transgene (A). Multicopy transgene integration was 
observed in dead off-spring generated from a 10x 50pl injection of 5.8x109 TU/ml shPOR-ve lentivirus (B). These animals were the 
only pups to show multiple integration events and died within three days of birth. SybrSafe image of digested DNA (ii) shows 
efficient digestion of DNA and similar loading of samples. 
 
 
 
presumably have higher shRNA expression levels and 
(based on our in vitro data) reduced POR activity, may 
have died in utero. Reduced growth rate seen in Hepa-1 
cells, reduced blastocyst development and the following 
observations in the animal studies support this scenario. 
 
In all 10x injections the pups were either re-absorbed or 
consumed at birth by the mother, in the one litter that 
survived (shPOR-ve) all the pups had died within 3 days.  
Where DNA samples were isolated from dead animals, 
Southern blot data indicated multiple copies of the 
transgene (Figure 2). The majority of 1x injections led to 
successful pregnancies although a low level of transgenesis 
was obtained (8/29; 27.5%) and all transgenic animals only 
contained one copy of the transgene (Figure 2b). For shPOR 
lentivirus injections less than half identified pregnancies (at 
day 10 gestation) resulted in births. If embryonic lethality 
was occurring it could result from high levels of shRNA 
(irrespective of target) which has been reported to cause 
mortality due to competitive inhibition of the endogenous 
miRNA system (Castanotto et al, 2007; Gimm et al, 2007) 
or reflect the known phenotypic consequence of 
significantly reducing POR activity during development 
(Shen et al 2005). 
i)
ii)
15kb –
6kb – i) ii)
9.4kb –
4.3kb –
2kb –
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A: 
 
 
B: 
 
 
C: 
 
 
 
Figure 3. POR expression in shRNA1 transgenic mice. 
Microsomal protein extracts were taken from liver samples of 21 
day old pups and POR protein levels determined by Western blot 
with average densitometry data normalized to β-actin protein 
levels of three separate blots with Standard Deviation error bars 
(A). Cytochrome C reductase activity (B) of microsomal protein 
with Standard Deviation error bars from three repeats of each 
assay. Non-transgenic samples 1-5 and transgenic samples 6-11.  
The correlation between protein expression and function is 
shown (C) where expression is plotted against function. 
 
 
Limited success has been noted when conjugated antisense 
oligonucleotides were delivered to the rat liver where a 
small reduction in POR reductase activity was seen 
(Venkateswaran et al, 2010).  In this study the antisense 
oligos were delivered using a non-viral delivery system 
which allowed large doses of the oligonucleotides to be 
delivered into adult rats, and despite a modest reduction in 
function, no significant change was seen in the protein 
expression level. This, together with our findings, suggests 
that POR is hard to specifically knockdown in vivo using 
RNAi and antisense technologies, indicating that more 
factors may be involved than the just previously reported 
embryonic lethality. 
 
CONCLUSIONS 
 
The overall aim of this study was to generate robust and 
versatile cell and animal systems that exhibited varying 
levels of POR activity, more accurately modelling the 
human population for pharmacological and toxicology 
studies. Specifically, altering POR activity would allow 
the role of cytochrome P450 activity on drug metabolism 
to be determined, enabling identification of bioavailability, 
efficacy and characterisation of drug metabolites to 
efficacy and toxicity to be evaluated (Henderson et al, 
2003; Finn et al, 2007).  
 
Although this study clearly demonstrates that both POR 
protein level and reductase activity can be significantly 
knocked down in Hepa-1 cells in vitro, the data also 
highlight the difficulty in knockdown of POR in an animal 
model. We believe that for strategies aiming to deliver 
gene knockdown in transgenic animals, the prior testing of 
RNAi constructs in cell systems is not necessarily a 
reliable indicator of subsequent in vivo activity. This study 
demonstrates that POR is a difficult target to knock down 
in vivo and inability to produce multi-copy transgenic 
animals suggests that a high level of shRNA expression is 
detrimental to the development of the embryo. 
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